Note: Descriptions are shown in the official language in which they were submitted.
~13~667
IN VITRO TEST FOR HELICOBACTER PYLORI
The present invention relates generally to a method and
kit which permit the rapid in vitro detection of
Helicobacter pylori infection in mammals. More
particularly, the present invention contemplates a method
for the detection of IgG antibodies against H. pylori in
mucous secretions and thereby provides a means to monitor
contemporary infection by the microbe in m~mm~l S.
Gut infections in m~mm~l S, and in particular humans,
stimulate an immune response in mucous secretions, such
as saliva, through activation of the common mucosal
immune system. This response often initially parallels
an antibody response in serum although is generally
characterised by the presence of IgA antibodies.
However, the immune response in secretion, including
saliva, rapidly diminishes following elimination of the
antigen (eg bacteria or virus) from the body.
Accordingly, the presence of antibody in mucous
secretions reflects current, ie contemporary, infection.
In the case of a microbial infection, for example,
antibodies in mucous secretions, hereinafter referred to
as secretious antibodies, reflect the current status of
colonisation of the microbe, such as in the gut, and thus
is a useful monitor of contemporary infection. Serum
antibody, on the other hand, persists for some time after
the microbe is eliminated from the body. A positive
serum antibody test, therefore, reflects both past and
present exposure to antigen which is less helpful to the
clinician. A positive secretious antibody test, on the
other hand, indicates present or contemporary infection
by the microbe.
2 - 2 11 34667
The present invention arose following an inve~tigation
into Helicobacter pylori (also known as Campylobacter
pylori) infection in the gut of mammals. The diaynosis of
H. pylori infection can be made by microscopy,
microbiological culture or urease detection in gastric
mucosal biopsies, urea breath test or by the presence of
specific antibodies in serum ELISAs. It might be
predicted that ~. pylori infection, being an infection o~
the gastric mucosa, would elicit an I~A antibody response
in gastric secretion. ~Iowever during work prior to the
present invention, it was discovered that H. pylori-
specific antibody in mucous secretions is of the IgG
class and not IgA as ~ight have been expected. Little
IgA antibody, if any, is detected. Accordingly, AU-A-
9067676 is directed to the detection of IgG in mucous
secretion specific to H. pylori antigen and thereby
provides a means of monitoring current, ie contemporary,
in~ection by that microorganism in mammals. The
corresponding academic publication is Witt et al,
Frontiers in Mucosal Immunology 1 693-696 (1991).
The presence of IgG antibodies in the saliva of
Campylobacter pylori positive patients has received some
attention in the proceedings of the Annual Meetings of
~he American Gastroenterological Association. After the
disclosure by Czinn et al [Gastroenterology, (1989~ Vol.
96 No. 5 part 2] of the presence of such antibodies in the
1989 proceedings, Larsen et al [Gastroenterology, (1991)
Vol. 100 No. 5 part 2] concluded in the May 1991
proceedings that salivary IgG levels are a practical, non-
invasive marker of therapeutic response during a course of
antibiotic therapy. In the April 1992 proceedings, Landes
et al [Gastroenterology, (1992) Vol. 102 No. 4 part 2]
confirmed earlier observations and observed that
measurement of salivary IgG to Helicobacter pylori i8 a
simple, non-invasive test for detecting N. pylori
r21~;~4667
positive patients, especially in widespread or paediatric
populations where other tests are not practical.
It is clear from the above that there is widespread
interest in, and clinical potential for, a salivary IgG
based diagnostic test for H. pylori. Equally, it is
clear that such a test must be reliable as well as
convenient. Invasive techniques are known (eg from US-~-
4882271, Schaber et al, ~. Clin. Microbiol. 27 (2) 327-330
(1989), Lo~feld et al, The L~ncet, 27 May 1989, 1182-11~5
and Evans et al, Gastroenterology 96 1004-1008 (1989) )
and established (eg the CLOTEsT kit which is available
from Delta West Ltd, Perth, Western Australia and which
detects the presence o~ urease in biopsy samples). A
non-invasive test must rival ~he reliability of invasive
tests for it to become accepted and useful.
The present invention relates to improving the
reliability of saliva-based (and other mucous-based) IgG
tests for H. pylori. It has been found that the
immunological specificity of the test method can be
improved by detecting mucous IgG by using certain
antigens from H. pylorl and by avoiding the use of
another.
According to a first aspect of the present invention,
there is provided a method for detecting contemporary
infection by Helicobacter pylori in a mammal, the method
comprising contacting a mucous secretion from the mammal
with an antigen preparation from H. pylori for a time and
under conditions sufficient for an IgG antibody in the
mucous secretion specific to the antigen component to form
a complex therewith and then subjecting the complex to a
detecting means in order to detect the complex, wherein
the antigen preparation consists essentially of H. pylori-
derived components of 238.5-291.5 kDa, as determined by
4 ~-2 ~ 3~67
native PAGE, and 306-374 kDa, a~ determined by native
PAGE, and is substantially free of an H. pylori-derived
component of 440 kDal as determined by native PAGE.
The present invention thus provides an effective in vitro
assay for H. pylori infection by screening for IgG
antibodies in mucous secretions.
It has been found that if the ca. 44~ kDa component is
present, false positives can occur in certain patients.
If the ca. 265 kDa antigen is absent false negatives may
occur. Additionally, if a ca. 340 kDa antigen derived
from H. pylori is not present, false negatives may occur
in certain patients; the presence of the ca. 340 kDa
antigen is therefore highly preferred. Other antigen
components from H. pylori which may, but do not have to
be, present include those with molecular weights of about
160 kDa and a~out 70 kDa.
An antigen component is present, for the purposes of this
invention, if it is detectable by Western blot analysis.
Conversely, it is absent if it is not detectable by this
means. The usually accepted sensitivity of Western blot
analysis is in the order of 20 ~g/ml.
Molecular weights of antigen components use~ul in the
present invention are of necessity approximate figures,
because of the limitations of current molecular weight
determination procedures. The molecular wéights
specifically referred to have been obtained by a native
polyacrylamide gel electrophoresis (PAGE) system sold by
Pharmacia under the trademarks PHASTGEL and P~STSYSTEM,
using the PHASTGEL gradient 8-25. This system gives a
linear relationship between a protein' 9 migration
.,
213~667
distance and the logarithm of its molecular weight for
the molecular weight range 50,000 to 750,000 for globular
proteins. Pharmacia provide a set of high molecular
weight markers in their electrophoresis calibration kit;
S this marker set was used to calibrate the gels referred
to in this specification. Those skilled in the art will
be aware that slightly different results can be obtained
in different hands or even on different occasions in the
same hands, and so the approximate molecular weight
figures quoted in this specification should be read as
+5~ or even +10~. For this reason the ca. 265 kDa
antigen is sometimes referred to as the 255-275 kDa
antigen.
The expression "antigen~ is used in its broadest sense
and includes whole H. pylori cells or homogeneous, near
homogeneous or heterogeneous extracts from H. pylori, all
of which are capable of binding to specific antibody in
a mucous secretion; providing always that ca . 265 kDa
(and preferably ca. 340 kDa) H. pylori-derived antigens
are present and a ca. 440 kDa H. pylori-derived antigen
is substantially absent. Antigen components contemplated
by the present invention include protein, polysaccharide
or lipid or any combination thereof. Preferably, the
antigen is protein, lipopolysaccharide or cell extract of
H. pylori prepared by, for example, sonication, pressure
disintegration, detergent extraction or fractionation.
One of the most effective methods of ensuring that the
necessary antigens are present, while removing many
irrelevant components, is the use of chromatography on
crude extracts (for example sonicates) of H. pylori
cells. For example, fast protein liquid chromatography
(FPLC), such as using a SUPEROSE 6 size exclusion column,
2131667
is particularly effective when applied to a crude
sonicate of cells which has been subjected to ion-
exchange chromatography. Other methods will be well
within the abilities of those skilled in the art.
Correspondingly, one of the most effective methods of
ensuring that the unwanted ca. 440 kDa antigen is absent
is the use of freeze drying on an extract of H. pylori
cells, particularly after chromatographic purification
such as FPLC. Freeze drying may be carried out in any
suitable apparatus for the purpose. The actual equipment
and conditions used will depend on the scale of the
preparation. It is preferred that the freeze drying
process is carried out substantially to completion,
within the limits of the equipment used.
The invention extends to the use of naturally occurring
form of antigens and to synthetic (eg recombinant) forms
and immunologically active derivatives, analogues and
relatives thereof. It is therefore clear that an
effective antigen set for use in the present invention
can either be selectively stripped down from an H. pylor
cell preparation or built up from individual components
or mixtures of components.
In the method of the invention, antibody is detected in
mucous secretion. By "mucous secretion" is meant the
secretion from mucous-secreting epithelial cells (ie
mucous membrane) such as those which line the canals,
cavities and tracts that communication with the external
air, and in particular the nose, throat, respiratory
tract, eyes, genital and urinary passages and the
digestive system. In preferred embodiments, the mucous
secretion is nasal secretion, sputum or, particularly,
saliva.
2131667
The saliva or other mucous secretion may be assayed
undiluted or diluted with an appropriate diluent (such as
distilled water). with increasing sensitivities,
dilution may be preferred (particularly when collection
devices are used).
The antigen preparation will for convenience and
preference be bound to a solid support. Suitable solid
supports include a nitrocellulose membrane, glass or a
polymer. The most commonly used polymers for this
purpose are cellulose, polyacrylamide, nylon,
polystyrene, polyvinyl chloride or polypropylene, but the
invention is not limited to them. The solid supports may
be in the form of strips, tubes, beads, discs or
microplates, or any other surface suitable for conducting
an immunoassay.
Antigen components of H. pylori useful in this invention
may be either covalently or non-covalently ("passively")
bound to the solid surface. Suitable binding processes
are well known in the art and generally consist of cross-
linking, covalently binding or physically adsorbing the
antigen to the solid support.
Infection is diagnosed by means of the present invention
by detecting the formation of a complex between IgG
antibody in a mucous sample and H. pylori antigens. Some
form of detecting means is therefore necessary to
identify the presence (or, if required, amount) of the
antibody-antigen complex.
The detection means may be a second antibody, conjugated
with a reporter molecule, and which is specific for at
least part of the class of H. pylori-specific antibody
213~667
found in the secretion; as explained above, that antibody
is IgG.
A "reporter molecule" is a molecule or group which, by
its chemical nature, has an analytically identifiable
characteristic or provides an analytically identifiable
signal which allows the detection of antigen-bound
antibody. Detection may be either qualitative or
quantitative. The most commonly used reporter molecules
in this type of assay are either enzymes, fluorophores or
radionuclide containing molecules (ie radioisotopes). In
the case of an enzyme immunoassay, an enzyme is
conjugated to the second antibody, generally by means of
glutaraldehyde or periodate. As will be readily
recognised, however, a wide variety of different
conjugation techniques exist, which are readily available
to those skilled in the art. Commonly used enzymes
include horseradish peroxidase, glucose oxidase, ~-
galactosidase and alkaline phosphatase, among others.
The substrates to be used with the specific enzymes are
generally chosen for the production, upon hydrolysis by
the corresponding enzyme, of a detectable colour change.
Substrates can be soluble or insoluble, depending upon
the chosen application. For example, 5-bromo-4-chloro-3-
indolyl phosphate/nitroblue tetrazolium is suitable foruse with alkaline phosphatase conjugates; for peroxidase
conjugates, l,2-phenylenediamine-5-aminosalicylic acid,
3,3,5,5-tetramethylbenzidine, tolidine or dianisidine are
commonly used. It is also possible to employ fluorogenic
substrates, which yield a fluorescent product, rather
than the chromogenic substrates noted above. ~xamples of
fluorogenic substrates are fluorescein and rhodamine.
When activated by illumination with light of a particular
wavelength, the fluorochrome-labelled antibody absorbs
2I3~ 667
the light energy, inducing a state of excitability in the
molecule, followed by emission of the light at a
characteristic colour which is usually visually
detectable with a light microscope. Immunofluorescence
and EIA techniques are both well established in the art
and are particularly preferred for the present method.
However, other reporter molecules, such as radioisotope,
chemiluminescent, and bioluminescent molecules and/or
dyes and other chromogenic substances, may also be
employed.
The choice of a particular reporter molecule conjugated
antibody will be, for the most part, determined by the
intended use and user of the present invention.
Additionally, although the test is appropriate for all
mammals susceptible to H. pylori infections, it is most
applicable and useful to monitoring H. pylori infection
in humans.
Accordingly, in a preferred embodiment, the present
invention provides a method for detecting contemporary
infection by H. pylori in a human comprising:
(a) contacting a mucous secretion from the human
with an antigen preparation of H. pylori immobilised
onto a solid support for a time and under conditions
sufficient for IgG antibody in the mucous secretion
specific to antigen in the antigen preparation to
form a complex therewith, wherein the antigen
preparation comprises H. pylori -derived components
of about 265 kDa and about 340 kDa and is
substantially free of an H. pylori-derived component
of about 440 kDa;
2131667
(b) contacting the complex with an effective amount
of a second antibody labelled with a reporter
molecule and specific to the H. pylori-specific IgG
antibody; and
(c) detecting binding of the second antibody to said
IgG antibody by the reporter molecule.
Hence, a medical practitioner, clinician, nurse or even
patient may use a nitrocellulose or other suitable solid
phase support membrane strip carrying immobilised H.
pylori antigens, such as freeze dried, FPLC-fractionated
soluble sonicate. The strip is then contacted with the
mucous secretion for a time and under conditions
sufficient to allow potential H. pylori specific
antibodies of the IgG class in saliva to bind to the
immobilised antigens. Instead of saliva, the source of
mucous secretion may be nasal secretion or sputum.
The test strip, once exposed to mucous secretion, is then
allowed to come into contact with a second antibody
conjugated with a reporter molecule for a time and under
conditions sufficient for the second antibody to bind to
the first antibody. Preferably, the reporter molecule is
an enzyme, such as alkaline phosphatase. The test strip
is then washed and a substrate for the reporter molecule,
(in the case where the reporter molecule is alkaline
phosphatase, 5-bromo-4-chloro-3-indolyl
phosphate/nitroblue tetrazolium), is brought into contact
with the strip. The substrate reacts with the reporter
molecule, thereby giving a detectable change. For
example, alkaline phosphatase hydrolyses 5-bromo-4-
chloro-3-indolyl phosphate to a purple product. This
entire procedure can occur in the medical practitioner's
surgery or office.
2134667
When a more quantitative enzyme-linked immunosorbent
assay (ELISA) is required, such as in a clinical
laboratory, a microtitre tray may be used carrying
immobilised H. pylori antigens in the wells of the tray.
In this case, samples of mucous secretion, eg saliva, are
added to the well to allow potential H. pylori - specific
IgG antibodies to bind to the immobilised antigen.
Excess secretion is washed away and a second antibody
specific to IgG conjugated to a reporter molecule is
added to allow an antigen-antibody-conjugated antibody
complex to form. This complex is detected by adding a
substrate to the reporter molecule as described above to
allow, for example, a visual signal which may then be
quantitated spectrophotometrically or by other means.
The invention may be embodied, alternatively or
additionally in an immunoblot system, which may also be
quantitative (for example by measuring intensity of
colour of the blot and/or distance migrated through a
chromatographic strip.
The present invention, especially when in the form of the
nitrocellulose strip, has many advantages over the
present commercially available assays for H. pylori. The
use of mucous secretion, and in particular saliva, to
assay for H. pylori antibody enables diagnosis of current
or contemporary infection and thus enables the medical
practitioner to:
a) Link gut symptoms with H. pylori which would
enable decisions to be made with respect to
further investigation (including invasive
procedures) and/or management (eg use of
specific anti-H. pylori agents). The latter
12 r 2 1 3 4 6 6 7
may be expected to have special significance
with respect to H. pylori-associated non-ulcer
dyspepsia, gastritis, duodenal ulceration,
gastric ulceration and related and other
conditions.
b) Have for the first time a convenient non-
invasive test iII the doctor's room, clinic or
hospital to follow patients with proven peptic
ulcer to detect early recurrence. A positive
test enables early diagnosis and prevention or
early treatment of recurrent peptic ulcer. A
negative test has a reciprocal usefulness in
analysis of the diagnostic approach to
dyspepsia.
Additionally, the test contemplated by the present
invention provides a simple yes/no answer, not requiring,
for example, the taking of blood. It can be read in
minutes and developed without any special preparation of
specimen by the clinician. A significant advantage of
the present invention is the use of mucous secretion (eg
saliva) to test for antibodies specific to H. pylori.
According to a second aspect of the present invention,
there is provided a test kit for detecting H. pylori in
mucous secretion of a mammal, said test kit comprising:
(a) a solid support having an antigen preparation of
3~ H. pylori immobilised thereon, wherein the antigen
preparation consists essentially of H. pylori-derived
components of 238.5-291.5 kDa, as determined by native
PAGE, and 306-374 kDa, as determined by native PAGE,
and is substantially free of an H. pylori-derived
component of 440 kDa, as determined by native PAGE; and
13 ~ 2 ~1 3 4 1~ 6 7
(b) detection means which in use detect whether IgG
in the said mucous secretion binds to one or more
components of the antigen preparation.
The detection means may be an antibody conjugated with a
reporter molecule which is capable of producing or giving
rise to a detectable signal; the antibody would be
specific against IgG antibody of the mammal in question.
In a preferred embodiment, the reporter molecule is an
enzyme capable of catalysing a reaction in which the
product(s) is or are detectably different from the
reactant(s). In such a case, a substrate for the enzyme,
which may for example have different colorimetric
properties from the product of the enzyme, will usually
lS also be present in the kit.
Hence, in a preferred embodiment, the present invention
extends to a kit for detecting H. pylori-specific IgG
antibody in mucous secretions in a mammal, such as a
human, the test kit being in compartment form and
comprlslng:
(a) a first compartment adapted to contain a solid
support having an antigen preparation of H. pylori
immobilised thereon, wherein the antigen preparation
comprises H. pylori-derived components of about 265
kDa and about 340 kDa and is substantially free of
an H. pylori-derived component of about 440 kDa;
(b) a second compartment containing an antibody
conjugated with a reporter molecule capable of
producing a signal, the antibody being specific
against IgG antibody; and
14 ~ 3 4 ~ ~ 7
(c) when the reporter molecule is an enzyme, a third
compartment containing a substrate for said enzyme.
The kit may also contain additional compartments such as
to receive suitable mucous material and/or for one or
more diluents and/or buffers. The kit may also be
packaged for sale in a suitable form.
The combination of the ca. 265 kDa and ca. 340 kDa
antigens in the absence of the ca. 440 kDa antigen from
H. pylori is useful in practising the method of the first
aspect of the invention and in the preparation of kits in
accordance with the second aspect of the invention.
According to a third aspect of the invention, therefore,
there is provided an H. pylori antigen preparation
consisting essentially of H. pylori-derived components of
238.5-291.5 kDa, as determined by native PAGE, and 306-374
kDa, as determined by native PAGE, and being substantially
free of an H. pylori-derived component of 440 kDa, as
determined by native PAGE .
Such an antigen preparation can be prepared, as
previously indicated, by freeze-drying an extract of
H. pylori cells to remove the ca. 440 kDa antigen.
According to a fourth aspect of the invention, therefore,
there is provided a process for the preparation of an
antigen preparation as described above, the process
comprising freeze-drying an extract of H. pylori cells.
The extract which is subjected to freeze drying is
preferably a ca. 67 kDa to ca. 440 kDa fraction
obtainable by size exclusion chromatography of a crude
H. pylori extract.
Other preferred features of each aspect of the invention
are as for the other aspects, mutatis mutandis.
.~
213~667
The following examples illustrate the invention but do
not limit its scope.
EXAMPLE 1
In this example, a crude sonicate of H. pylori is
prepared, subjected to FPLC fractionation and freeze-
dried. Western blot analysis shows that approximately
265 and 340 kDa proteins are responsible factors in the
immunological specificity of the assay of the present
invention. These proteins only show reactivity in true
positives unlike a potentially contaminating 440 kDa
protein. This protein is removed by freeze-drying, to
which it appears to be sensitive.
Preparation of Helicobacter pylori antigen
Centrifuged Sonicate, includinq Anion Exchanqe
ChromatoqraphY
i) Cultures of ~. pylori are harvested from chocolate
agar plates in PBS. The bacteria are grown as two
separate cultures, a wild strain designated "Traub"
and an NCTC strain 11637.
ii) The bacteria are washed three times in PBS by
centrifugation for 5 minutes at lO,OOOxg.
iii) Washed bacteria are resuspended in 2ml of PBS and
CFUs are estimated by reading on a spectrophotometer
at 405nm.
iv) The suspension is subjected to 5 cycles of
sonication (30 seconds at 6~, followed by 60 seconds
rest which constitutes one cycle).
v) Sonicated organisms are centrifuged for 10 minutes
at lO,OOOxg.
vi) The supernatant is recovered and filtered through a
0.45~m filter, then a 0.22~m filter, to remove any
remaining cellular debris.
2134667
16
vii) After filtering, a protein estimation is performed.
Note: If it is not possible to process the
sonicate directly, it may be frozen down at
-70~C at this point in the method until an
opportunity arises to continue the method.
viii)The MONO Q anion exchange column can take 20-50 mg
of protein per 500 ~l injection (so the sonicate can
have up to 40-100 mg of protein per ml).
ix) At this point the sonicate usually needs
concentration in order to reduce the number of
injections necessary to process the whole sonicate,
and to increase the protein concentration to the
allowable level. Concentrating is carried out using
CENTRISART concentration tubes, with spins at 2500
rpm for 20 minutes each, at 4~C. The sonicate is
usually concentrated in order to give 2 to 3 x 500
~l injections.
x) After concentration, the preparation is put down the
MONO Q column in 500 ~l injections. A readout is
given for each injection and all parameters are
recorded.
xi) Once the preparation has been run through the MONO Q
fractions are checked for a urease peak.
xii) The values obtained from the urease test are plotted
onto the protein profile obtained from the FPLC (see
below). The required fractions are then pooled and
a protein estimation performed. This protein
concentration is used to determine the number of
spins needed to concentrate the pool to
approximately 1 ml. The preparation is concentrated
using CENTRISART concentration tubes.
FPLC Antiqenic Fractions
i) Sonicate is further purified by fast protein liquid
~1346G7
chromatography on a SUPEROSE 6 size exclusion column.
ii) The column is equilibrated with PBS pH 7.6-7.7
containing 0.02~ w/v sodium azide.
iii) 200~1 of sonicate are loaded onto the column and
0.5ml fractions collected.
iv) Fractions are collected and a urease test performed
to find the urease peak. The values are plotted
onto the readout obtained from the FPLC. The
required fractions are pooled.
v) A small aliquot is taken to perform a native PAGE
analysis to check consistency of bonding. These
fractions do not include the urease peak but
correspond to a peak representing a group of smaller
proteins with molecular weights between 440 kDa and
67 kDa.
vi) The remainder is stored at -20~C and later pooled
with other, similar preparations to form batches.
Freeze-drYin~
Antigen from the above batches is freeze dried in an FSE
Freeze Drier comprising:
(a) a Leybold (USA) TRIVAC pump, model No D4A;
(b) a General Electric (USA) 240 volt AC motor;
(c) a VIRTIS vacuum chamber (Virtis Co. Inc., New
York, USA); and
(d) a refrigeration unit incorporated into the
cabinet of the freeze drier.
30 ml of antigen-containing liquid, frozen at an angle in
a 5 cm diameter 50 ml specimen jar to increase surface
2134667
area, was placed within the vacuum chamber, and the
system operated. The temperature of the system in use was
always set on -55~C. The vacuum of the system in use was
kept at 80-100 mTorr (approximately 0.001 atmospheres);
the range value depends on the initial volume of frozen
liquid and its surface area and, hence, the amount of
vapour in the chamber. The sample was freeze-dried to
complete dryness, which took 16-18 hours.
Native Gradient-PAGE usin~ Pharmacia's PHASTSYSTEM
Antigens from the above fractions, before and after
freeze drying, are subjected to native PAGE using linear
gradient acrylamide gels and the protein profiles
visualised with rapid silver staining, as follows.~5
i) Buffer strips were PHASTGEL native buffer strips to
separate proteins in their native state.
ii) The gel was PHASTGEL Gradient 8-25. This system
gives a linear relationship between a protein's
migration distance and the log of its molecular
weight for the molecular weight range 50 kDa to 750
kDa for globular proteins.
iii) Markers used were Pharmacia's electrophoresis
calibration kit for high molecular weight
determinations. 1 vial (Cat. No. 17-0445-01) of
lyophilised marker was dissolved in 100 ~l distilled
water. Reconstituted marker was diluted 1/10 for
silver staining of gel. 1 ~1 marker was run in
duplicate.
iv) For the antigen sample, 1 ~l of each SUPEROSE 6 FPLC-
purified extract was run in duplicate.
v) Separation conditions: samples were run using
optimised method of native PAGE from PHASTSYSTEM
Separation Technique File No. 120. The length of
- 213~667
the run was 120 volt.hours.
vi) Development conditions: gel is silver stained
following the method from Table 3 from PHASTSYST~
Development Technique File No. 210 ("Silver Staining
Method Optimised for Native-PAGE").
vii) The molecular weight determination is obtained using
the high molecular weight markers that are run with
the antigens on the gel. Standard curves are
determined by plotting the log molecular weight
against the Rf value.
Comparison of Antiqens before and after Freeze-Dryinq
Using the above native-PAGE methodology, the following
results were obtained. Values are given as means plus or
minus one standard deviation. (n) indicates the number of
determinations that could be made from the gel.
Purified Freeze-dried
Antigen 1436+20.6 (4) Not detected (4)
Antigen 2338.6+14.1 (4)334.0+18.5 (4)
Antigen 3248.0+18.1 (4) 262.0+0 (2)
Antigen 4162.7+23.0 (3) 162.0 (1)
Antigen 570.0+0 (3) 70.0 (1)
Further Characterisation of Antiq,ens
i) Relative molecular masses may be estimated from
standard containing thyroglobulin, ferritin,
catalase, lactate dehydrogenase and albumin.~0 ii) Western blotting methods may be employed to detect
the appropriate protein bands by using sera positive
to H. pylori.
2134667
iii) FPLC fractionation removes those lower molecular
weight bands which are reactive with negative sera.
iv) The effect of freeze drying on the antigen
preparation appears to diminish the presence of a
large molecular weight (about 440 kDa) unit which is
reactive with false positive sera. The absence of
the 440 kDa band is important in the discrimination
between positive, false positive and negative sera.
The effect of this purification procedure is the
identification of a protein in the molecular weight range
255-275 kDa but generally about 265 kDa and a protein
whose molecular weight is about 340 kDa which are
reactive to positive sera but not negative sera.
EXAMPLE 2
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
1. Coatinq of ELISA plates with antiqen
i) Polystyrene ELISA plates are used (Polysorb,
Nunc, Denmark).
ii) Freeze dried antigen preparation from Example
1 is optimally diluted (highest dilution giving
maximum sensitivity for antibody positive saliva
without increasing reactivity of antibody negative
saliva) in coating buffer (see 2(iii) below).
iii) An aliquot of 100 ~l of diluted antigen is
added to "antigen~' wells of an ELISA plate and 100
~l of coating buffer (without antigen) is added to
"buffer" wells.
iv) Plates are incubated overnight at 4~C
temperature.
v) Incubated plates are emptied, an aliquot of
100~1 of 5~ w/v dried skim milk powder/coating
213~667
buffer (see 2(iii) below) added for 30 minutes and
emptied immediately by flicking the contents out.
2. Buffers
i) Phosphate buffered saline (PBS): 0.14M NaCl,
0.003M Na2HPO4, O.OOlN NaH2PO4.2H2O in 1 litre of
deionized water adjusted to pH 7.2.
ii) Substrate buffer: lO.lg citric acid, 14.2g
disodium hydrogen orthophosphate (Na2HPO4), 150~1
H2O2 (30~ w/v) in 1 litre of deionized water adjusted
to pH 5Ø
iii) Coating buffer: 2.42g TRIS[tris(hydroxymethyl)
amino methane], 58.44g NaCl, in 1 litre of deionized
water adjusted to pH 7.5.
3. Treatment of plates after antiqen coating
For long term storage (6 months) of antigen coated
plates, plates are dried after coating and blocking and
stored at 4~C with a desiccant. This procedure is
necessary for long term preservation of the antigen
coated plates.
4. ELISA Procedure
a) Horseradish Peroxidase method
i) An aliquot of 100 ~l of saliva diluted 1/2 in
0.05~ (w/v) dried skim milk powder/PBST (PBSTM) or
lOOul of saliva diluted 1/2 in PBSTM is added to an
antigen well and to a buffer well of the ELISA
plate.
ii) Plates are incubated for up to 90 minutes at
ambient temperature.
iii) Plates are washed 5 times by immersion in PBST.
iv) An aliquot of 100 ~l of horseradish peroxidase
anti-human IgG diluted optimally (highest dilution
2134667
giving maximum sensitivity for antibody positive
saliva without increasing reactivity of antibody
negative saliva) in PBSTM is added to antigen and
buffer wells.
v) Plates are incubated for up to 90 minutes at
ambient temperature.
vi) Plates are washed 5 times by immersion in PBST.
vii) An aliquot of 100 ~1 of horseradish peroxidase
substrate (Product T-2885, Sigma, USA) in substrate
buffer is added to antigen and buffer wells.
viii) Plates are incubated for up to 30 minutes
at ambient temperature.
ix) 100 ~l of lM H2S04 is added to antigen and
buffer wells.
x) For each serum or saliva sample, the absorbence
(A) of the buffer well is subtracted from the A of
the antigen well and the resultant A is converted to
ELISA units using a standard curve (constructed from
doubling dilutions of a standard antibody positive
serum).
xii) A survey of 100 saliva from patients who had
been demonstrated by biopsy to be infected (or not
infected) is used to determine the number of ELISA
units corresponding to infection.
EXAMPLE 3
IMMUNOBLOTTING ASSAY
1. Pre~aration of Helicobacter pylori antiqen
The procedure for the preparation of H. pylori antigen
for the immunoblotting assay is identical to that in
Example 1.
2134667
2. Coating of the membrane with antiqen
i) Nitrocellulose membrane is used. Nylon based
membranes can also be used.
ii) After blotting dry, the membrane is soaked for
5 minutes in an optimal dilution of antigen (highest
dilution of antigen giving maximum sensitivity with
antibody positive samples without producing positive
reactions in antibody negative samples).
iii) The membrane is then incubated for 30 minutes
in 5~ (w/v) skim milk powder/TBS.
iv) The membrane is washed twice for 5 minutes in
0.05~ (w/v) polyoxyethylene sorbitan monolaurate/TBS
(TBST). For long term storage (up to 18 months) the
membrane is then dried and stored at 4~C with a
desiccant.
v) The membrane is immersed for up to 5 minutes in
undiluted test saliva in a test bottle or under the
tongue.
vi) The membrane is washed for 30 seconds under
running tap water.
vii) The membrane is immersed in alkaline
phosphatase-conjugated anti-human IgG optimally
diluted (to enable distinction between antibody
positive and antibody negative saliva) in PBSTM for
up to 5 minutes.
viii)The membrane is washed for 30 seconds under
running tap water.
ix) The membrane is immersed for 5 minutes in
substrate (0.3mg nitroblue tetrazolium, 0.15mg 5-
bromo-4-chloro-3-indolyl phosphate in lml O.lM
NaHCO3, l.OmM MgCl2, pH 9.8).
x) Antibody positive samples produce a mauve
colour change in the antigen region of the membrane
whereas antibody negative samples do not alter the
colour of the membrane in the antigen region.
2134667
24
EXAMPLE 4
Patients referred to the Gastroenterology Department,
Royal North Shore Hospital, NSW, for investigation of
upper gastro-intestinal symptoms were studied.
Microbiological culture, microscopy for the detection of
H. pyl ori, urease tests, and histology of gastric
biopsies and ELISAs were performed on all patients where
possible.
Correlation of salivary antibodies with biopsy tests for
H. pyl ori
The relationship between gastric biopsy histology and
saliva ELISA results together with other tests for
l S H. pyl ori infection are shown in the following table.
A serum ELISA has been shown to be more sensitive and
specific than the biopsy tests in detecting H. pyl ori
infection and is becoming generally accepted as the
"gold" standard for detection of H. pylori infections.
The results in this table show that the salivary assay
system performs equally as well as serum. Where no
inflammation or chronic inflammation is present, all
tests currently available, including urease, culture and
histology, perform relatively equally. However, patients
with active inflammation are indicated as having
H. pylori infection more often with both the serum and
salivary ELISA than with other systems. The reason for
this may be the fact that the biopsy is a fairly random
sampling procedure and may miss areas of H. pylori
infestation. As can be seen the saliva ELISA results
correlate well with the serum ELISA results.
RELATIONSHIP BETWEEN ELISAs AND BIOPSY TESTS WITH GASTRIC HISTOLOGY
Gastric Serum Saliva CLO Culture Histology
Inflammation ~ + ~ + - + - + - +
NONE 5 0 5 0 5 0 5 0 5 0
CHRONIC 3 1 3 1 3 1 3 1 3
ACTIVE 1 12 2 11 4 8 4 8 3 10
2134667
26
Those skilled in the art will appreciate that the
invention described herein is susceptible to variations
and modifications other than those specifically
described. It is to be understood that the invention
includes all such variations and modifications. The
invention also includes all of the steps, features,
compositions and compounds referred to or indicated in
this specification, individually or collectively, and any
and all combinations of any two or more of said steps or
features.
